MIR34A host gene: A promising drug target and biomarker (G106614088)
MIR34A host gene: A promising drug target and biomarker
MIR34A, a gene located on chromosome 6p21.1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function in the body and its potential as a drug target are explored in this article.
MIR34A gene and its function
MIR34A is a non-coding RNA gene that encodes a protein known as MIR34A-host, a protein that is expressed in various tissues and organs, including brain, heart, liver, and muscle. The protein is composed of 218 amino acids and has a molecular weight of 24.1 kDa.
MIR34A-host is involved in various cellular processes, including cell adhesion, migration, and invasion. It is a key regulator of the Shc/FAZ signaling pathway, a pathway that regulates cell-cell adhesion and that is implicated in various diseases, including cancer.
MIR34A-host has also been shown to play a role in the regulation of cell cycle progression. It is involved in the G1/S transition, which is a critical step in the cell cycle and is associated with the G1 phase.
MIR34A-host as a drug target
MIR34A-host is a promising drug target because of its involvement in various cellular processes that are implicated in various diseases. Its involvement in the Shc/FAZ signaling pathway and cell cycle regulation makes it a potential target for small molecules that can modulate these pathways.
MIR34A-host has also been shown to be involved in the regulation of cell survival and pro-inflammatory responses. It has been shown to play a role in the regulation of cell apoptosis, which is a natural mechanism of cell death that is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival.
MIR34A-host has also been shown to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of immune cell function and the production of pro-inflammatory cytokines.
MIR34A-host as a biomarker
MIR34A-host has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been shown to be altered in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
MIR34A-host has also been shown to be involved in the regulation of cancer cell survival and the development of cancer. Its expression has been shown to be altered in various types of cancer, including breast, ovarian, and colorectal cancer.
MIR34A-host has also been shown to be involved in the regulation of neurodegenerative diseases. Its expression has been shown to be altered in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
MIR34A-host has also been shown to be involved in the regulation of autoimmune disorders. Its expression has been shown to be altered in various autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.
MIR34A-host as a potential drug and biomarker
MIR34A-host is a promising drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in the Shc/FAZ signaling pathway and cell cycle regulation makes it a potential target for small molecules that can modulate these pathways.
MIR34A
Protein Name: MIR34A Host Gene
The "MIR34AHG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR34AHG comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR34B | MIR34C | MIR3529 | MIR3591 | MIR3605 | MIR3606 | MIR3609 | MIR361 | MIR3610 | MIR3611 | MIR3612 | MIR3613 | MIR3614 | MIR3615 | MIR3616 | MIR3617 | MIR3618 | MIR3619 | MIR362 | MIR3620 | MIR3621 | MIR3622A | MIR3622B | MIR363 | MIR3646 | MIR3648-1 | MIR3649 | MIR3650 | MIR3651 | MIR3652 | MIR3654 | MIR3655 | MIR3658 | MIR3659 | MIR365A | MIR365B | MIR3660 | MIR3661 | MIR3662 | MIR3663 | MIR3664 | MIR3665 | MIR3667 | MIR3667HG | MIR3668 | MIR367 | MIR3670-1 | MIR3670-2 | MIR3671 | MIR3672 | MIR3674 | MIR3675 | MIR3677 | MIR3678 | MIR3679 | MIR3680-1 | MIR3680-2 | MIR3681 | MIR3681HG | MIR3682 | MIR3683 | MIR3685 | MIR3686 | MIR3687 | MIR3688-1 | MIR3688-2 | MIR3689A | MIR3689B | MIR3689C | MIR3689D1 | MIR3689D2 | MIR3689F | MIR369 | MIR3690 | MIR3691 | MIR3692 | MIR370 | MIR3713 | MIR3714 | MIR371A | MIR371B | MIR372 | MIR373 | MIR374A | MIR374B | MIR374C | MIR375 | MIR376A1 | MIR376A2 | MIR376B | MIR376C | MIR377 | MIR378A | MIR378B | MIR378C | MIR378D1 | MIR378D2 | MIR378E | MIR378F | MIR378G
